Drug intelligence / Profile preview

11C-JNJ-63779586

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

11C-JNJ-63779586 is a Carbon-11 radiolabeled small molecule developed by Janssen Research & Development as a positron emission tomography (PET) imaging tracer. It specifically targets the **Breast Cancer Resistance Protein (BCRP)**, also known as **ABCG2**, which is an efflux transporter found at the blood-brain barrier (BBB). By acting as a substrate for BCRP, the tracer allows for the non-invasive quantification of BCRP-mediated efflux activity in the human brain. This is particularly relevant in drug development and the study of central nervous system (CNS) disorders like Alzheimer's disease, where changes in BBB transporter function can significantly impact the pharmacokinetics and efficacy of therapeutic agents. Clinical studies have utilized 11C-JNJ-63779586 to investigate regional brain kinetics and compare transporter function between healthy individuals and patients with mild Alzheimer's disease.

Other names: carbon C 11-JNJ-63779586

Targets

ABCB1 (P-glycoprotein)ABCG2 (Breast cancer resistance protein)

Beyond the preview

Go deeper on 11C-JNJ-63779586.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-JNJ-63779586.

Explore the full profile